Clinical Trial of HG146 Administered to Participants With Adenoid Cystic Carcinoma

This is a Phase II, open-label, non-randomized, multicenter study to evaluate the clinical efficacy and safety of HG146 in participants with recurrent or metastatic adenoid cystic carcinoma. This study is divided into two stages. 40 participants will be enrolled in the first stage. The efficacy and safty data will apply to make go or no go decision. Then the second stage will continue to enroll 100 Particapants.

Trial Details

NCT ID
NCT06781567
Phase
PHASE2
Sponsor
HitGen Inc.
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • HG146
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Signed informed consent form (ICF) and able to comply with study.
  • Age ≥18 years, gender unlimited.
  • Recurrent or metastatic adenoid cystic carcinoma with evidence of disease progression (imaging progression or clinical evidence of progression) wit…
  • Estimated survival \>12 weeks, as determined by the investigator.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →